Company / Operating Cash Flow
ELITE PHARMACEUTICALS INC /NV/ Operating Cash Flow History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$7.5M
FY2024
5-year range
-$3.2M / $7.5M
FY2020-FY2024
Trend
+330.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed +330% YoY in FY2024, a notable deviation from the 8-year average annual change of +67%.
Based on SEC 10-K filings.
$7M in FY2024 with a 3-year CAGR of +4.6%.
Improved from $3M to $7M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +4.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +4.6%, indicating consistent growth.
- In FY2024, operating cash flow increased 330.5% year-over-year.
- Lowest operating cash flow in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $7.5M | +330.5% |
| FY2023 | -$3.2M | -196.9% |
| FY2022 | $3.3M | -48.7% |
| FY2021 | $6.5M | +103.8% |
| FY2020 | $3.2M | +278.0% |
| FY2019 | -$1.8M | +73.6% |
| FY2018 | -$6.8M | -41.2% |
| FY2017 | -$4.8M | +39.0% |
| FY2016 | -$7.9M | -185.1% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026